The Experts below are selected from a list of 96 Experts worldwide ranked by ideXlab platform

Fiona Hughes - One of the best experts on this subject based on the ideXlab platform.

  • A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
    PloS one, 2016
    Co-Authors: D. Fullen, Bryan Murray, Ganesh Balaratnam, Julie Mori, Andrew Catchpole, Anthony Gilbert, Daryl W. Borley, Edward J. Murray, Alex Mann, Fiona Hughes
    Abstract:

    Background Human Rhinovirus infection is an important precursor to asthma and chronic obstructive pulmonary disease exacerbations and the Human Viral Challenge model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new Wild-Type HRV-16 challenge virus produced specifically for this purpose. Methods and Stock Development A HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer (University of Virginia Children’s Hospital, USA) was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 Cell Line under Good Manufacturing Practice conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we conducted an initial safety and pathogenicity clinical study in adult volunteers in our dedicated clinical quarantine facility in London. Human Challenge and Conclusions In this study we have demonstrated the new Wild-Type HRV-16 Challenge Virus to be both safe and pathogenic, causing an appropriate level of disease in experimentally inoculated healthy adult volunteers. Furthermore, by inoculating volunteers with a range of different inoculum titres, we have established the minimum inoculum titre required to achieve reproducible disease. We have demonstrated that although inoculation titres as low as 1 TCID50 can produce relatively high infection rates, the optimal titre for progression with future HRV challenge model development with this virus stock was 10 TCID50. Studies currently underway are evaluating the use of this virus as a challenge agent in asthmatics. Trial Registration ClinicalTrials.gov NCT02522832

  • LATE-BREAKING ABSTRACT: Discovering new treatments for asthma and COPD. The use of the human viral challenge model with a newly manufactured and characterised GMP human rhinovirus
    1.1 Clinical Problems, 2015
    Co-Authors: D. Fullen, Bryan Murray, Ganesh Balaratnam, Julie Mori, Andrew Catchpole, Anthony Gilbert, Fiona Hughes, Rob Lambkin-williams
    Abstract:

    Human Rhinovirus (HRV) infection is an important precursor to asthma and chronic obstructive pulmonary disease (COPD) exacerbations and, therefore, an HRV Human Viral Challenge Model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new HRV-16 challenge virus produced specifically for this purpose. An HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 Cell Line under Good Manufacturing Conditions (GMP) conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we then conducted an initial safety and pathogenicity clinical study in adult volunteers, in our dedicated clinical quarantine facility in London. In this study we demonstrated the new HRV-16 challenge virus to be both safe and pathogenic causing an appropriate level of disease in healthy adult volunteers. By inoculating volunteers with a range of different inoculum titres, we have established the minimum inoculum titre required to achieve reproducible disease. We have demonstrated that inoculation titres as low as 1 TCID50 can still produce relatively high infection rates. The optimal titre determined for progression with future HRV challenge model development with this virus stock was 10 TCID50. Studies currently underway are evaluating the use of this virus as a challenge agent in asthmatics.

Hong Zhong - One of the best experts on this subject based on the ideXlab platform.

  • Relationship between methylation status of multi-drug resistance protein(MRP) and multi-drug resistance in lung cancer Cell Lines
    Chinese Journal of Cancer Research, 2007
    Co-Authors: Rui-jun Liu, Hong Zhong
    Abstract:

    To study the relationship between the methylation status of multi-drug resistance protein (MRP) gene and the expression of its mRNA and protein in lung cancer Cell Lines. Human embryo lung Cell Line WI-38, lung adenocarcinoma Cell Line SPCA-1 and its drug-resistant Cells induced by different concentrations of doxorubicin were treated with restriction endonuclease Eco47III. The methylation status of MRP was examined by PCR, and the expressions of its mRNA and protein were evaluated by in situ hybridization and immunohistochemistry. MRP gene promoter region of WI-38 Cells was in hypermethylation status, but the promoter region of MRP in SPCA-1 Cells and their resistant derivatives induced by different concentrations of doxorubicin were in hypomethylation status. There were significant differences in the expression of MRP mRNA among WI-38 Cell Line, SPCA-1 Cells and their drug-resistant derivatives induced by different concentration of doxorubicin. Consistently, MRP immunostaining presented similar significant differences. The promoter region of MRP in SPCA-1 lung adenocarcinoma Cells was in hypomethylation status. The hypomethylation status of 5′ regulatory region of MRP promoter is an important structural basis that can increase the activity of transcription and results in the development of drug resistance in lung cancer.

D. Fullen - One of the best experts on this subject based on the ideXlab platform.

  • A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
    PloS one, 2016
    Co-Authors: D. Fullen, Bryan Murray, Ganesh Balaratnam, Julie Mori, Andrew Catchpole, Anthony Gilbert, Daryl W. Borley, Edward J. Murray, Alex Mann, Fiona Hughes
    Abstract:

    Background Human Rhinovirus infection is an important precursor to asthma and chronic obstructive pulmonary disease exacerbations and the Human Viral Challenge model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new Wild-Type HRV-16 challenge virus produced specifically for this purpose. Methods and Stock Development A HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer (University of Virginia Children’s Hospital, USA) was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 Cell Line under Good Manufacturing Practice conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we conducted an initial safety and pathogenicity clinical study in adult volunteers in our dedicated clinical quarantine facility in London. Human Challenge and Conclusions In this study we have demonstrated the new Wild-Type HRV-16 Challenge Virus to be both safe and pathogenic, causing an appropriate level of disease in experimentally inoculated healthy adult volunteers. Furthermore, by inoculating volunteers with a range of different inoculum titres, we have established the minimum inoculum titre required to achieve reproducible disease. We have demonstrated that although inoculation titres as low as 1 TCID50 can produce relatively high infection rates, the optimal titre for progression with future HRV challenge model development with this virus stock was 10 TCID50. Studies currently underway are evaluating the use of this virus as a challenge agent in asthmatics. Trial Registration ClinicalTrials.gov NCT02522832

  • LATE-BREAKING ABSTRACT: Discovering new treatments for asthma and COPD. The use of the human viral challenge model with a newly manufactured and characterised GMP human rhinovirus
    1.1 Clinical Problems, 2015
    Co-Authors: D. Fullen, Bryan Murray, Ganesh Balaratnam, Julie Mori, Andrew Catchpole, Anthony Gilbert, Fiona Hughes, Rob Lambkin-williams
    Abstract:

    Human Rhinovirus (HRV) infection is an important precursor to asthma and chronic obstructive pulmonary disease (COPD) exacerbations and, therefore, an HRV Human Viral Challenge Model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new HRV-16 challenge virus produced specifically for this purpose. An HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 Cell Line under Good Manufacturing Conditions (GMP) conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we then conducted an initial safety and pathogenicity clinical study in adult volunteers, in our dedicated clinical quarantine facility in London. In this study we demonstrated the new HRV-16 challenge virus to be both safe and pathogenic causing an appropriate level of disease in healthy adult volunteers. By inoculating volunteers with a range of different inoculum titres, we have established the minimum inoculum titre required to achieve reproducible disease. We have demonstrated that inoculation titres as low as 1 TCID50 can still produce relatively high infection rates. The optimal titre determined for progression with future HRV challenge model development with this virus stock was 10 TCID50. Studies currently underway are evaluating the use of this virus as a challenge agent in asthmatics.

Rui-jun Liu - One of the best experts on this subject based on the ideXlab platform.

  • Relationship between methylation status of multi-drug resistance protein(MRP) and multi-drug resistance in lung cancer Cell Lines
    Chinese Journal of Cancer Research, 2007
    Co-Authors: Rui-jun Liu, Hong Zhong
    Abstract:

    To study the relationship between the methylation status of multi-drug resistance protein (MRP) gene and the expression of its mRNA and protein in lung cancer Cell Lines. Human embryo lung Cell Line WI-38, lung adenocarcinoma Cell Line SPCA-1 and its drug-resistant Cells induced by different concentrations of doxorubicin were treated with restriction endonuclease Eco47III. The methylation status of MRP was examined by PCR, and the expressions of its mRNA and protein were evaluated by in situ hybridization and immunohistochemistry. MRP gene promoter region of WI-38 Cells was in hypermethylation status, but the promoter region of MRP in SPCA-1 Cells and their resistant derivatives induced by different concentrations of doxorubicin were in hypomethylation status. There were significant differences in the expression of MRP mRNA among WI-38 Cell Line, SPCA-1 Cells and their drug-resistant derivatives induced by different concentration of doxorubicin. Consistently, MRP immunostaining presented similar significant differences. The promoter region of MRP in SPCA-1 lung adenocarcinoma Cells was in hypomethylation status. The hypomethylation status of 5′ regulatory region of MRP promoter is an important structural basis that can increase the activity of transcription and results in the development of drug resistance in lung cancer.

Bryan Murray - One of the best experts on this subject based on the ideXlab platform.

  • A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
    PloS one, 2016
    Co-Authors: D. Fullen, Bryan Murray, Ganesh Balaratnam, Julie Mori, Andrew Catchpole, Anthony Gilbert, Daryl W. Borley, Edward J. Murray, Alex Mann, Fiona Hughes
    Abstract:

    Background Human Rhinovirus infection is an important precursor to asthma and chronic obstructive pulmonary disease exacerbations and the Human Viral Challenge model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new Wild-Type HRV-16 challenge virus produced specifically for this purpose. Methods and Stock Development A HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer (University of Virginia Children’s Hospital, USA) was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 Cell Line under Good Manufacturing Practice conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we conducted an initial safety and pathogenicity clinical study in adult volunteers in our dedicated clinical quarantine facility in London. Human Challenge and Conclusions In this study we have demonstrated the new Wild-Type HRV-16 Challenge Virus to be both safe and pathogenic, causing an appropriate level of disease in experimentally inoculated healthy adult volunteers. Furthermore, by inoculating volunteers with a range of different inoculum titres, we have established the minimum inoculum titre required to achieve reproducible disease. We have demonstrated that although inoculation titres as low as 1 TCID50 can produce relatively high infection rates, the optimal titre for progression with future HRV challenge model development with this virus stock was 10 TCID50. Studies currently underway are evaluating the use of this virus as a challenge agent in asthmatics. Trial Registration ClinicalTrials.gov NCT02522832

  • LATE-BREAKING ABSTRACT: Discovering new treatments for asthma and COPD. The use of the human viral challenge model with a newly manufactured and characterised GMP human rhinovirus
    1.1 Clinical Problems, 2015
    Co-Authors: D. Fullen, Bryan Murray, Ganesh Balaratnam, Julie Mori, Andrew Catchpole, Anthony Gilbert, Fiona Hughes, Rob Lambkin-williams
    Abstract:

    Human Rhinovirus (HRV) infection is an important precursor to asthma and chronic obstructive pulmonary disease (COPD) exacerbations and, therefore, an HRV Human Viral Challenge Model may provide a powerful tool in studying these and other chronic respiratory diseases. In this study we have reported the production and human characterisation of a new HRV-16 challenge virus produced specifically for this purpose. An HRV-16 isolate from an 18 year old experimentally infected healthy female volunteer was obtained with appropriate medical history and consent. We manufactured a new HRV-16 stock by minimal passage in a WI-38 Cell Line under Good Manufacturing Conditions (GMP) conditions. Having first subjected the stock to rigorous adventitious agent testing and determining the virus suitability for human use, we then conducted an initial safety and pathogenicity clinical study in adult volunteers, in our dedicated clinical quarantine facility in London. In this study we demonstrated the new HRV-16 challenge virus to be both safe and pathogenic causing an appropriate level of disease in healthy adult volunteers. By inoculating volunteers with a range of different inoculum titres, we have established the minimum inoculum titre required to achieve reproducible disease. We have demonstrated that inoculation titres as low as 1 TCID50 can still produce relatively high infection rates. The optimal titre determined for progression with future HRV challenge model development with this virus stock was 10 TCID50. Studies currently underway are evaluating the use of this virus as a challenge agent in asthmatics.